Evidence map›Paper›PMID 34826547›Full record

ArticleCancer letters2022

PKCθ-mediated serine/threonine phosphorylations of FAK govern adhesion and protrusion dynamics within the lamellipodia of migrating breast cancer cells.

Lucie Chadelle, Jiaying Liu, Valérie Choesmel-Cadamuro, Andrei V Karginov, Carine Froment, Odile Burlet-Schiltz, Sarah Gandarillas, Yara Barreira, Christele Segura, Loïc Van Den Berghe and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Lucie ChadelleMCD, Centre de Biologie Intégrative (CBI), Université de Toulouse, CNRS, UPS, 31062, Toulouse, France.
Jiaying LiuMCD, Centre de Biologie Intégrative (CBI), Université de Toulouse, CNRS, UPS, 31062, Toulouse, France.
Valérie Choesmel-CadamuroMCD, Centre de Biologie Intégrative (CBI), Université de Toulouse, CNRS, UPS, 31062, Toulouse, France.
Andrei V KarginovDepartment of Pharmacology and Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Carine FromentInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.
Odile Burlet-SchiltzInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.
Sarah GandarillasService d'Expérimentation Animale, UMS 006/CREFRE Inserm/UPS, 31059, Toulouse, France.
Yara BarreiraService d'Expérimentation Animale, UMS 006/CREFRE Inserm/UPS, 31059, Toulouse, France.
Christele SeguraPole Technologique UMR1037, CRCT (Cancer Research Center of Toulouse), INSERM, UPS, F-31037, Toulouse, France.
Loïc Van Den BerghePole Technologique UMR1037, CRCT (Cancer Research Center of Toulouse), INSERM, UPS, F-31037, Toulouse, France.
Georges CzaplickiInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.
Nathalie Van AckerCHU Toulouse, Institut Universitaire du Cancer Toulouse - Oncopole; Département d'Anatomie Pathologique, 1 Avenue Irène-Joliot-Curie, 31059, Toulouse Cedex, France.
Florence DalencInstitut Claudius Regaud, Institut Universitaire du Cancer Toulouse - Oncopole; Département d'oncologie Médicale, 1 Avenue Irène-Joliot-Curie, 31059, Toulouse Cedex, France.
Camille FranchetInstitut Claudius Regaud, Institut Universitaire du Cancer Toulouse - Oncopole; Département d'Anatomie Pathologique, 1 Avenue Irène-Joliot-Curie, 31059, Toulouse Cedex, France.
Klaus M HahnDepartment of Pharmacology and Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Xiaobo WangMCD, Centre de Biologie Intégrative (CBI), Université de Toulouse, CNRS, UPS, 31062, Toulouse, France. Electronic address: xiaobo.wang@univ-tlse3.fr.
Karine BelguiseMCD, Centre de Biologie Intégrative (CBI), Université de Toulouse, CNRS, UPS, 31062, Toulouse, France. Electronic address: karine.belguise@univ-tlse3.fr.
Centre National de la Recherche Scientifique · FRUniversité Toulouse III - Paul Sabatier · FRInstitut Claudius Regaud · FRUniversity of North Carolina at Chapel Hill · USInstitut universitaire du cancer de Toulouse Oncopole · FR

Funding

Dissecting signaling in vivo via precise control and visualization of protein activityR35GM122596 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Klaus M. Hahn · 2017 to 2026
$7.4M
NIGMS NIH HHS R35 GM122596
6 · The paper itself

Abstract

The cytoskeleton and cell-matrix adhesions constitute a dynamic network that controls cellular behavior during development and cancer. The Focal Adhesion Kinase (FAK) is a central actor of these cell dynamics, promoting cell-matrix adhesion turnover and active membrane fluctuations. However, the initial steps leading to FAK activation and subsequent promotion of cell dynamics remain elusive. Here, we report that the serine/threonine kinase PKCθ participates in the initial steps of FAK activation. PKCθ, which is strongly expressed in aggressive human breast cancers, controls the dynamics of cell-matrix adhesions and active protrusions through direct FAK activation, thereby promoting cell invasion and lung metastases. Using various tools for in vitro and live cell studies, we precisely decipher the molecular mechanisms of FAK activation. PKCθ directly interacts with the FAK FERM domain to open FAK conformation through PKCθ's specific V3 domain, while phosphorylating FAK at newly identified serine/threonine residues within nascent adhesions, inducing cell dynamics and aggressive behavior. This study thus places PKCθ-directed FAK opening and phosphorylations as an original mechanism controlling dynamic, migratory, and invasive abilities of aggressive breast cancer cells, further strengthening the emerging oncogenic function of PKCθ.

Indexed as

AnimalsBreast NeoplasmsCell AdhesionCell Line, TumorCell MovementCytoskeletonFemaleFocal Adhesion Kinase 1HeterograftsHumansMCF-7 CellsMiceMice, Inbred BALB CMice, NudePhosphorylationProtein Kinase C-thetaFocal Adhesion Kinase 1Protein Kinase C-thetaProtein Serine-Threonine KinasesPTK2 protein, humanCancer cell migration and invasionCell dynamicsFAKPhosphorylationPKCθ

Identifiers

PMID34826547
PMCPMC9019305
OpenAlexW3217331388

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.